Research programme: fibromyalgia therapies - Cypress Bioscience/Georgetown University
Latest Information Update: 11 Jan 2008
At a glance
- Originator Cypress Bioscience; Georgetown University School of Medicine
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Fibromyalgia
Most Recent Events
- 02 Apr 2001 Preclinical development for Fibromyalgia in USA (Unknown route)